EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients

ConclusionsGiven these data we conclude that EZH2 mutations are frequent in our patients, and can be used as a prognosis marker in combination with FLT3, IDH2 mutations and CD7 marker, to stratify AML patients and to guide therapeutic decisions.
Source: Advances in Medical Sciences - Category: Biomedical Science Source Type: research